Associations between FAS rs2234767 and FASL rs763110 polymorphisms and the risk of lung cancer: a meta-analysis of 39,736 subjects.
BACKGROUND
Previous studies have investigated the associations between the common polymorphisms in FAS/FASL genes and lung cancer risk; however, the results remain inconsistent and inconclusive. Hence, we performed a meta-analysis to reassess the relationships between FAS rs2234767 and FASL rs763110 polymorphisms and the risk of lung cancer.


METHODS
Eligible studies retrieved by an electronic search were pooled to calculate the strength of the associations using the odds ratio (OR) and 95% confidence interval (95% CI).


RESULTS
A total of 13 case-control studies involving 39,736 subjects (9,237 cases and 10,838 controls on FAS rs2234767 and 8,957 cases and 10,704 controls on FASL rs763110) were included in the meta-analysis. The results showed a significant association between FAS rs2234767 polymorphism and increased risk of lung cancer (A vs G: OR =1.07, 95% CI =1.01-1.13; AA vs GG: OR =1.23, 95% CI =1.06-1.43; AA vs GA + GG: OR =1.24, 95% CI =1.08-1.43). Similar association was also observed in Asian population (AA vs GA + GG: OR =1.30, 95% CI =1.01-1.67) and in the studies with large sample size (A vs G: OR =1.07, 95% CI =1.00-1.14; AA vs GG: OR =1.30, 95% CI =1.07-1.58). However, no significant association between FASL rs763110 polymorphism and lung cancer risk was found other than in the Asian population (CC vs TC + TT: OR =1.35, 95% CI =1.01-1.80).


CONCLUSIONS
The meta-analysis indicated that FAS rs2234767 polymorphism was significantly associated with an increased risk of lung cancer and FASL rs763110 polymorphism may not contribute to susceptibility to lung cancer other than in Asian population.
Department of Oncology, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Xiongjie
X
Yu
Department of Endocrinology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Yanli
Y
Li
Department of Oncology, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Yuandong
Y
Yu
Department of Oncology, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Jinhua
J
Lei
Department of Oncology, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Guoxing
G
Wan
Department of Oncology, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
Fengjun
F
Cao
FAS; FAS ligand; apoptosis; lung cancer; meta-analysis; polymorphism; risk